NEW YORK, July 25 - Diversa, a San Diego-based microbial genomics firm, announced today that the National Institute of Allergy and Infectious Diseases was prepared to award the company approximately $3.2 million to optimize three antibodies that the U.S. army is already using for the detection of bioterrorism agents.


To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.